Drug Trial Radar · NCT05611229
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
Last checked: Nov 20, 2026Latest source record: Apr 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,975
Actual
Start
Jun 16, 2020
Primary completion
Dec 3, 2021
Study completion Dec 3, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 9, 2022
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.
Conditions
- Metastatic Melanoma
Interventions
NivolumabDrug
Nivolumab
PembrolizumabDrug
Pembrolizumab
Dabrafenib+TrametinibCombination product
Dabrafenib+Trametinib
Ipilimumab+NivolumabCombination product
Ipilimumab+Nivolumab
Vemurafenib+CobimetinibCombination product
Vemurafenib+Cobimetinib
Encorafenib+BinimetinibCombination product
Encorafenib+Binimetinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients receiving TT and IO therapy in the first-, and second-lineTime frame: throughout the study period, approximately 6 years (i.e., 01 January 2014 to 30 August 2020 for population 1 and 01 January 2014 to 31 May 2020 for population 2
- Proportion of patients switching from TT 1L therapy to IO 2L therapyTime frame: throughout the study period, approximately 6 years (i.e., 01 January 2014 to 30 August 2020 for population 1 and 01 January 2014 to 31 May 2020 for population 2
- Proportion of patients switching from IO 1L therapy to TT 2L therapyTime frame: throughout the study period, approximately 6 years (i.e., 01 January 2014 to 30 August 2020 for population 1 and 01 January 2014 to 31 May 2020 for population 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
East Hanover, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.